In this podcast series, Dr. Jenny Seligmann (University of Leeds, UK), Dr. Autumn McRee (University of North Carolina, USA) and Dr. Dominik Modest (Charité University of Medicine, Germany) discuss the different therapeutic options available in colorectal and gastric cancer.
In this third episode, the experts turn their focus to earlier stage disease and consider how lessons learnt in the treatment of metastatic disease can be applied in the neo adjuvant setting for colorectal cancer by discussing data from the FOXTROT and NICHE trials and the adjuvant setting for gastric cancer by discussing data from CheckMate 577. Finally, the experts consider new promising data on targeting KRAS compared to the MEK and the ERK inhibitors.
Brenda Martone, a nurse practitioner at Northwestern Medicine in Chicago Illinois and Dr Alicia Morgans, Genitourinary Medical Oncologist at the Dana-Farber Cancer Institute in...
Episode 2: Navigating common treatment scenarios in HER2-mutant NSCLC This is the second episode of a two-part series on the HER2 diagnostic and treatment...
What are the challenges and considerations when using real-world evidence to inform your clinical practice? How can data from real-world studies be used to...